Oregon Health & Science University

Michael Cohen

Rory Morgan

Ilsa Kirby

Paolo Bernardi

Aaron Nilsen

Michael Forte

Jordan Devereaux

Haihong Jin

Lulu Cambronne

Melissa Stewart

Ian Carter-O'Connell

Sunil K Sundalam

Justina Sileikyte

Richard Goodman

Provided herein are novel compounds, compositions, that can used as clickable, photo-affinity labeling (PAL) probes methods for use in screening NAD+ binding proteins.

Platform for screening NAD+ binding proteins in a cellular context

Provided are substituted 8-methylquinazolin-4(3H)-one compounds useful as PARP inhibitors for the treatment of cancer and asthma, as well as pharmaceutical compositions comprising them and methods for their synthesis.

PARP inhibitors for treating cancer and asthma

The present invention provides compounds useful as mitochondrial permeability transition pore (mtPTP) inhibitors, the compounds being of Formula (I), or a pharmaceutically acceptable salt thereof wherein Ris selected from the group of H, halogen, and C-Calkyl; and Ris selected from the group of H, CF, and halogen; with the proviso that at least one of Rand Ris halogen or CF.

Second generation inhibitors of mitochondrial permeability transition pore with improved plasma stability

Mutant mono ADP-ribose-polymerases (mono-PARP) proteins and small molecule compound substrates specific for the mutant mono-PARP proteins as well as methods of using these compositions to identify protein targets of the mono-PARPs and to screen for antagonists of the mono-PARPs are described.

Compounds and methods used in assessing mono-PARP activity

Provided herein are compounds of Formula I, or a pharmaceutically acceptable salt thereof: which are useful as PARP inhibitors, as well as pharmaceutical compositions comprising them and methods for their use in treating disorders.

Inhibitors of PARPs that catalyze mono-ADP-ribosylation

A polypeptide biosensor that detects free NADis disclosed. The polypeptide comprises a first fragment from an NADdependent DNA ligase acetylation domain, a second fragment from the NADdependent DNA ligase acetylation domain, and a fluorescent protein, wherein the fluorescent protein is positioned between the two DNA ligase acetylation domain fragments. Also disclosed are expression vectors comprising the biosensor as well as methods of using the biosensor to detect NAD.

Growing community of inventors

Portland, OR, United States of America

Michael Cohen